Despite advancements in treatments for metastatic non‐small cell lung cancer (NSCLC), patients harboring sensitizing epidermal growth factor receptor (EGFR) mutations ultimately experience treatment failure with frontline tyrosine kinase inhibitors (TKIs) [1, 2]. The gene discussed is EGFR; the disease is lung cancer.